GC Biopharma · SERPINC1 · 细胞治疗
antithrombin III 是一种细胞治疗，由GC Biopharma研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。
| 公司 | GC Biopharma |
| 药物类别 | 细胞治疗 |
| 分子靶点 | SERPINC1 |
| 给药途径 | Injectable (Others), Intravenous (IV) |
| 状态 | Approved |
antithrombin III 作用于 1 个分子靶点：
| SERPINC1 | serpin family C member 1 (ATIII, AT3D) |
antithrombin III 针对 1 个适应症，涉及 1 个治疗领域。
| 治疗领域 | 疾病/病症 | 分期 |
|---|---|---|
| Congenital, familial and genetic disorders | Antithrombin III deficiency | ✓ Approved |
Zhao Ya Y, Yin Jian J, Song Jia J, Zhao Yuqi Y et al.
A pregnant woman with hereditary antithrombin deficiency was managed with adjusted-dose LMWH throughout pregnancy, monitoring D-dimer and anti-Xa activity, successfully preventing thrombosis and hemorrhage.
Ma Zuchao Z, Pequegnat Brittany B, Hodgins Douglas D, Sagermann Martin M et al.
Clostridioides difficile polysaccharides (PSs) represent useful tools for the study of C. difficile pathogenesis. Water-soluble PS-I (pentaglycosyl-phosphate repeats) and PS-II (hexaglycosyl-phosphate repeats) and phenol-soluble lipoteichoic acid (LTA) PS-III have been previously identified. Most of the LTA PS-III repeats consist of two N-acetyl-glucopyranosamine (GlcNAc) units and glyceric acid (GroA), bridged by an exocyclic phosphodiester: →P-6)-α-D-GlcNAc-(1-3)-α-D-GlcNAc-[1-2-GroA]-(6→. Here, we describe a water-soluble PS from an equine C. difficile strain similar to PS-III, but with 6-substituted glucopyranosamine (GlcN) predominantly in the repeat: →P-6)-α-D-GlcN-(1-3)-α-D-GlcNAc-[1-2-GroA]-(6→ (coined wsPS-III). For analytical comparisons, the two saccharides, α-D-GlcN-(1-3)-α-D-GlcNAc-(1-2)-GroA and α-D-GlcNAc-(1-3)-α-D-GlcNAc-(1-2)-GroA, were chemically synthesized, and the transformation product, Gro-(1-P-6)-α-D-GlcNAc-(1-2)-GroA, was generated by Smith degradation. Pre-existing circulating IgG antibodies in horse sera due to natural exposure reacted with wsPS-III, and inoculation of rabbits with wsPS-III afforded IgG antibodies that reacted with C. difficile. It is postulated that the zwitterionic nature of wsPS-III is the driving force behind the observed solubility and immunogenicity. The glycans presented here will be useful in investigations concerning C. difficile biosynthetic pathways, virulence, antibiotics and vaccines.
Xiang Yongbo Y, Bi Nan N
This article discusses the emerging radiotherapy-free and chemo-free strategies in PD-L1-high, unresectable stage III NSCLC, reviewing the Evolution trial and comparing it with existing treatments. We highlight the need for further research to validate these approaches and ensure safe de-escalation without compromising curability.
Gao Ying Y, He Biyun B, Huang Jing J, Pan Yang Y
Existing pediatric burn studies have primarily focused on risk factors or survival outcomes, while predictors of hospital length of stay (LOS) remain insufficiently explored. This study aimed to develop and validate a nomogram predicting LOS by incorporating the clinical characteristics of children with II-III degree scald burns. This retrospective study collected cases of pediatric patients with II-III degree scald burns admitted to Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Children and Adolescents' Health and Diseases between July 2024 and August 2025. A generalized linear regression model for predicting LOS was established based on univariate Gamma regression, multicollinearity tests, and multivariate Gamma regression to screen variables, followed by construction of a nomogram. Model performance and calibration were internally validated using root mean square error (RMSE), mean absolute error (MAE), cross-validation, and 1,000-times bootstrap resampling. A total of 191 children (male: 64.9%; female: 35.1%) with II-III degree scald burns were included, with the majority aged between 1 and 3 years. Multivariate analysis showed that burn time before admission, total body surface area, albumin, blood glucose, white blood cell count, hemoglobin and skin condition were independent predictors of LOS in children with II-III degree scald burns. The model established had the lowest Akaike information criterion value, indicating the best fit. The Gamma generalized linear model demonstrated moderate predictive performance with a cross-validated R2 of 0.31, along with acceptable calibration and mild optimism in bootstrap internal validation. We constructed a nomogram to predict LOS in children with scald burns, which may help clinicians assess LOS early and optimize treatment.
Huang Szu-Wei SW, Lin Hao H, Huang Chao-Cheng CC, Ou Yu-Che YC et al.
To evaluate the prognostic value of estrogen receptor (ER) expression in mismatch repair-proficient (MMRp) stage III endometrial cancer (EC) in an Asian cohort using an immunohistochemistry (IHC) - based molecular classification, we retrospectively analyzed patients with stage III EC classified by IHC into three molecular subtypes: mismatch repair-deficient (MMRd), TP53-mutant, and MMRp. The MMRp group was further stratified by ER expression (10% cutoff) into ER-positive and ER-negative subgroups, yielding four molecular subtypes. Clinicopathological features and survival outcomes were compared. Ninety-five patients were included: 7 (7.4%) with MMRp ER-negative, 34 (35.8%) with MMRp ER-positive, 27 (28.4%) with MMRd, and 27 (28.4%) with TP53-mutant tumors. With a median follow-up of 61 months, progression-free survival (PFS) and cancer-specific survival (CSS) differed significantly across four IHC-based subtypes (log-rank P = 0.0013 and P<0.0001, respectively). In multivariate Firth's penalized Cox regression, MMRp ER-negative status was an independent predictor of poor PFS (HR 4.91; 95% CI, 1.43-15.80) and CSS (HR 7.44; 95% CI, 1.85-30.80), independent of histologic grade. Even within low-risk MMRp endometrioid grade 1-2 tumors, ER-negativity identified a high-risk subset (12.1%, 4/33). To our knowledge, this is among the first studies to evaluate the prognostic relevance of ER expression in stage III MMRp EC in an Asian cohort using a pragmatic IHC-based approach. Low ER expression identified a distinct high-risk subgroup whose outcomes approached those of TP53-mutant tumors.
Yamazaki Nozomi N, Hanaoka Marie M, Yamauchi Shinichi S, Kagawa Hiroyasu H et al.
Robot-assisted colectomy has been increasingly adopted for colon cancer because of its technical advantages; however, evidence regarding its short- and survival oncological outcomes remains limited. The aim of this study was to compare short- and survival outcomes among open, laparoscopic, and robot-assisted colectomy (OC, LC, and RAC) for stage I-III colon cancer using a large real-world database. This multicenter retrospective cohort study analyzed 43,540 patients with clinical stage I-III colon cancer who underwent colectomy between April 2022 and September 2025 using the Japanese Medical Data Vision database. To adjust for baseline differences across surgical approaches, overlap weighting was applied, yielding an effective sample size of 34,236 patients. Primary outcomes included postoperative complications, perioperative mortality, length of hospital stay, and hospitalization costs. Secondary outcomes were overall survival (OS) and recurrence-free survival (RFS). After overlap weighting, 3,694 patients underwent RAC, 25,975 underwent LC, and 4,567 underwent OC. The RAC group demonstrated the lowest rates of postoperative complications, intraoperative blood transfusion, and 30- and 90-day mortality, as well as the shortest hospital stay and lowest hospitalization costs. The 3-year OS rates were 95, 94, and 90% in the RAC, LC, and OC groups, respectively (p < 0.001), with corresponding RFS rates of 94, 92, and 88%. Compared with LC and OC, RAC for stage I-III colon cancer was associated with favorable short-term outcomes and survival profiles. Prospective studies with longer follow-up are warranted to clarify its survival oncological impact.
注册免费账户还可查看另外 9996 篇文献
免费注册查看全部文献 →